THE second part of Frontline's interview with David Baltimore, the reputed American biologist and Nobel laureate, includes a discussion on a wide range of issues including his own research; funding in health-related research and development; the "moral conundrum' of high investments in product development by drug companies versus making drugs affordable for the less developed world; intellectual property rights and generic drugs; policies of the United States on issues affecting scientific research; and open access to research communication. The interview, the first part of which was published in the last issue of Frontline dated February 29, was given partly in New Delhi and partly in Bangalore during Baltimore's lecture tour of India in January. Excerpts: The crowd for your lecture in Bangalore on microRNAs must have been quite a surprise to you. Yes. I was amazed. But what I heard later was that there were so many people who were turned away. Maybe 2,000 people